Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Cited by (1,021)

Items 201–300 of 1,021

1. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
   Benjamin Besse, A. Adjei, P. Baas, Peter Meldgaard, Marianne C. Nicolson, Luis G Paz-Ares, Martin Reck, Egbert Frederik Smit, Konstantinos Syrigos, Rolf Arno Stahel et al. · 2014 · Annals of Oncology
2. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
   Dickran Gano Kazandjian, Gideon Michael Blumenthal, Weishi Yuan, Kun He, Patricia Keegan, Richard Pazdur · 2016 · Clinical Cancer Research
3. The Expanding World of N-MYC–Driven Tumors
   David S. Rickman, Johannes Hubertus Schulte, Martin Eilers · 2018 · Cancer Discovery
4. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
   Olga Rodak, Manuel David Peris‐Díaz, Mateusz Olbromski, Marzenna Podhorska‐Okołów, Piotr Dzięgiel · 2021 · Cancers
5. Treating ALK-positive lung cancer—early successes and future challenges
   Camidge, D. Ross, Doebele, Robert C. · 2012 · Nature Reviews Clinical Oncology
6. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
   Qing Hua Zhou, Chong‐Rui Xu, Ying Cheng, Yunpeng Liu, Gongyan Chen, Jiuwei Cui, Nong Yang, Yong Song, Xiaoling Li, Shun Lü et al. · 2021 · Cancer Cell
7. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
   Wu, Shang-Gin, Liu, Yi-Nan, Tsai, Meng-Feng, Chang, Yih-Leong, Yu, Chong-Jen, Yang, Pan-Chyr, Yang, James Chih-Hsin, Wen, Yueh-Feng, Shih, Jin-Yuan · 2016 · Oncotarget
8. Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
   David González de Castro, Paul Andrew Clarke, Bissan Al‐Lazikani, Paul Workman · 2012 · Clinical Pharmacology & Therapeutics
9. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
   Jessica J. Lin, Stephen V. Liu, Caroline Elizabeth McCoach, Viola Weijia Zhu, Aaron C. Tan, Satoshi Yoda, J. Peterson, Andrew Do, Kylie Prutisto-Chang, Ibiayi Dagogo‐Jack et al. · 2020 · Annals of Oncology
10. Epidermal growth factor receptor mutations in lung adenocarcinoma
    Markus David Siegelin, Alain Borczuk · 2013 · Laboratory Investigation
11. Resisting Resistance: Targeted Therapies in Lung Cancer
    Jessica J. Lin, Alice Tsang Shaw · 2016 · Trends in cancer
12. Targeting KRAS mutant cancers: from druggable therapy to drug resistance
    Zhu, Chunxiao, Guan, Xiaoqing, Zhang, Xinuo, Luan, Xin, Song, Zhengbo, Cheng, Xiangdong, Zhang, Weidong, Qin, Jiang-Jiang · 2022 · Molecular Cancer
13. Biology and evolution of poorly differentiated neuroendocrine tumors
    David S. Rickman, Himisha Beltran, Francesca Demichelis, Mark A. Rubin · 2017 · Nature Medicine
14. Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
    Venus Sosa Iglesias, Lorena Giuranno, Ludwig Jerome Dubois, Jan Theys, Marc Vooijs · 2018 · Frontiers in Oncology
15. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
    Labbé, Catherine, Cabanero, Michael, Korpanty, Grzegorz J., Tomasini, Pascale, Doherty, Mark K., Mascaux, Céline, Jao, Kevin, Pitcher, Bethany, Wang, Rick, Pintilie, Melania et al. · 2017 · Lung Cancer
16. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
    Erik Thunnissen, Keith M. Kerr, Felix J.F. Herth, Sylvie Lantuéjoul, Mauro Giulio Papotti, Robert Campbell Rintoul, Giulio Rossi, Birgit Guldhammer Skov, Birgit Weynand, Lukas Bubendorf et al. · 2011 · Lung Cancer
17. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
    Murtuza, Ayesha, Bulbul, Ajaz, Shen, John Paul, Keshavarzian, Parissa, Woodward, Brian D., Lopez-Diaz, Fernando J., Lippman, Scott M., Husain, Hatim · 2019 · Cancer Research
18. Characterization of the cell of origin for small cell lung cancer
    Kwon-Sik Park, Mei‐Chih Liang, David M. Raiser, Raffaella Zamponi, Rebecca R. Roach, Stephen J. Curtis, Zandra E. Walton, Bethany E. Schaffer, Caitlin M. Roake, Anne‐Flore Zmoos et al. · 2011 · Cell Cycle
19. Mechanisms of Acquired Resistance to AZD9291
    Tae Min Kim, Ahnah Song, Dong‐Wan Kim, Soyeon Kim, Yong‐Oon Ahn, Bhumsuk Keam, Yoon Kyung Jeon, Se‐Hoon Lee, Doo Hyun Chung, Dae Seog Heo · 2015 · Journal of Thoracic Oncology
20. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
    Di Zheng, Xue-Rui Ye, M. Z. Zhang, Yun Sun, J. Y. Wang, Jian Ni, H. P. Zhang, L. Zhang, Jie Luo, J. Zhang et al. · 2016 · Scientific Reports
21. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
    Zhen Wang, Jin‐Ji Yang, Jie Huang, Junyi Ye, Xu‐Chao Zhang, Hai‐Yan Tu, Han Han‐Zhang, Yi-Long Lung Cancer Wu · 2017 · Journal of Thoracic Oncology
22. Targeting the HGF/Met signaling pathway in cancer therapy
    Fabiola Cecchi, Daniel C. Rabe, Donald Paul Bottaro · 2012 · Expert Opinion on Therapeutic Targets
23. Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
    Sai‐Hong Ignatius Ou, Cynthia Huang Bartlett, Mari A. Mino-Kenudson, Jean Cui, Anthony John Iafrate · 2012 · The Oncologist
24. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
    Crispin T. Hiley, Elza C. de Bruin, Nicholas McGranahan, Charles Swanton · 2014 · Genome biology
25. Molecular pathways and therapeutic targets in lung cancer
    Shtivelman, Emma, Hensing, Thomas, Simon, George R., Dennis, Phillip A., Otterson, Gregory A., Bueno, Raphael, Salgia, Ravi · 2014 · Oncotarget
26. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    A. Gelatti, Alexander Edward Dela Cruz Drilon, Fernando Costa Santini · 2019 · Lung Cancer
27. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
    Wenjuan Liu, Yue Du, Ru M. Wen, Ming Yang, Jian Xu · 2019 · Pharmacology & Therapeutics
28. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
    Robert Jr. Roskoski · 2014 · Pharmacological Research
29. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
    Raoof, Sana, Mulford, Iain J., Frisco-Cabanos, Heidie, Nangia, Varuna, Timonina, Daria, Labrot, Emma, Hafeez, Nafeeza, Bilton, Samantha J., Drier, Yotam, Ji, Fei et al. · 2019 · Oncogene
30. Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
    J. Jean Cui · 2013 · Journal of Medicinal Chemistry
31. A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
    Mark A. Socinski, Jonathan Wade Goldman, Iman A. El‐Hariry, Marianna Koczywas, Vojo Vukovic, Leora Horn, Eugene Paschold, Ravi Salgia, Howard West, Lecia Van Dam Sequist et al. · 2013 · Clinical Cancer Research
32. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    Juliann Chmielecki, Tony S.K. Mok, Yi-Long Lung Cancer Wu, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih‐Hsin Yang, Frances A. Shepherd et al. · 2023 · Nature Communications
33. Drug resistance to targeted therapies: Déjà vu all over again
    Floris H. Groenendijk, René Bernards · 2014 · Molecular Oncology
34. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
    Benjamin Jacob Drapkin, Julie George, Camilla Laulund Christensen, Mari A. Mino-Kenudson, Ruben Dries, Tilak Kumar Sundaresan, Sarah Phat, David T. Myers, Jun Zhong, Peter Igo et al. · 2018 · Cancer Discovery
35. Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
    Apostolia Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald Steven Falchook, Siqing Fu, Sarina Anne Piha-Paul, Aung Naing, Filip Jankú, Kenneth Aldape et al. · 2014 · Clinical Cancer Research
36. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    J.L. Kuiper, Daniëlle A.M. Heideman, Erik Thunnissen, M.A. Paul, A.W. van Wijk, Pieter E. Postmus, Egbert Frederik Smit · 2014 · Lung Cancer
37. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
    Jia‐Jia Wu, Zhenghong Lin · 2022 · International Journal of Molecular Sciences
38. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
    Eugene M. Tulchinsky, Oleg N. Demidov, Marina V. Kriajevska, Nickolai A. Barlev, Евгений Наумович Имянитов · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
39. Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
    Henning Willers, Christopher G. Azzoli, Wil L. Santivasi, Fen Xia · 2013 · The Cancer Journal
40. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
    Antonio Passaro, Natasha B. Leighl, Fiona Helen Blackhall, Sanjay Popat, Keith M. Kerr, Myung‐Ju Ahn, Maria E. Arcila, Oscar G. Arrieta, David Planchard, Filippo de Marinis et al. · 2022 · Annals of Oncology
41. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S.W. Tan, Suresh S. Ramalingam, Caicun Zhou · 2024 · Nature Reviews Clinical Oncology
42. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
    Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal X. Rosen, Nathanael S. Gray, Kwok‐Kin Wong et al. · 2015 · Cancer Discovery
43. Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
    Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Sohei Nakayama, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shinnosuke Ikemura, Takashi Sato et al. · 2013 · Molecular Cancer Research
44. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
    Wind, Sven, Schnell, David, Ebner, Thomas, Freiwald, Matthias, Stopfer, Peter · 2017 · Clinical Pharmacokinetics
45. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
    Ruifang Dong, Miaolin Zhu, Mingming Liu, Yiting Xu, Liu-Liu Yuan, Jing Bian, Yuan‐Zheng Xia, Lingyi Kong · 2021 · Pharmacological Research
46. CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
    Andrea Walens, Ashley V. DiMarco, Ryan Lupo, Benjamin R. Kroger, Jeffrey S. Damrauer, James V. Alvarez · 2019 · eLife
47. Transferrin receptor targeting chimeras for membrane protein degradation
    Dingpeng Zhang, Jhoely Duque-Jimenez, Francesco Facchinetti, Garyk Brixi, Kaitlin Rhee, William W. Feng, Pasi Antero Janne, Xin X. Zhou · 2024 · Nature
48. NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
    Blakely, Collin M., Pazarentzos, Evangelos, Olivas, Victor, Asthana, Saurabh, Yan, Jenny Jiacheng, Tan, Irena, Hrustanovic, Gorjan, Chan, Elton, Lin, Luping, Neel, Dana S. et al. · 2015 · Cell Reports
49. Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
    Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice Tsang Shaw, Jeffrey A. Engelman, Naoya Fujita · 2014 · Clinical Cancer Research
50. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
    Rintu Thomas, Zhang Weihua · 2019 · Frontiers in Oncology
51. The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles
    Mohammad‐Javad Sanaei, Sara Razi, Atieh Pourbagheri‐Sigaroodi, Davood Bashash · 2022 · Translational Oncology
52. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
    Tatsushi Kodama, Toshiyuki Tsukaguchi, Miyuki Yoshida, Osamu Kondoh, Hiroshi Sakamoto · 2014 · Cancer Letters
53. Next-generation sequencing: advances and applications in cancer diagnosis
    Simona Serratì, Simona De Summa, Brunella Pilato, Daniela Petriella, Rosanna Lacalamita, Stefania Tommasi, Rosamaria Pinto · 2016 · OncoTargets and Therapy
54. Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling
    Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, Maria Catherine Pietanza, Maureen Frances Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi et al. · 2011 · Molecular Cancer Therapeutics
55. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
    Tan, Daniel S.W., Yom, Sue S., Tsao, Ming S., Pass, Harvey I., Kelly, Karen, Peled, Nir, Yung, Rex C., Wistuba, Ignacio I., Yatabe, Yasushi, Unger, Michael et al. · 2016 · Journal of Thoracic Oncology
56. Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
    Nader El-Sayes, Alyssa Vito, Karen Louise Mossman · 2021 · Cancers
57. Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
    Elza C. de Bruin, Catherine Cowell, Patricia H. Warne, Ming Zuo Jiang, Rebecca E. Saunders, Mary Ann Melnick, Scott N. Gettinger, Zenta Walther, Anna Wurtz, Guus J.J.E. Heynen et al. · 2014 · Cancer Discovery
58. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
    Yuxin Lin, Xian Wang, Hongchuan Jin · 2014 · Europe PMC (PubMed Central)
59. SnapShot: Non-Small Cell Lung Cancer
    Rebecca Suk Heist, Jeffrey A. Engelman · 2012 · Cancer Cell
60. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Xueli Nan, Chao Xie, Xueyan Yu, Jie Liu · 2017 · Oncotarget
61. Immune Resistance in Lung Adenocarcinoma
    Μάγδα Σπέλλα, Georgios T. Stathopoulos · 2021 · Cancers
62. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
    Isabel Coutinho, Tanya K. Day, Wayne D. Tilley, Luke A. Selth · 2016 · Endocrine Related Cancer
63. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma
    Xiangkun Han, Fuming Li, Zhaoyuan Fang, Yijun Gao, Fei Li, Rong Fang, Shun Yao, Yihua Sun, Li Li, Wenjing Zhang et al. · 2014 · Nature Communications
64. A basal stem cell signature identifies aggressive prostate cancer phenotypes
    Bryan A. Smith, Artem Sokolov, Vladislav Uzunangelov, Robert Baertsch, Yulia Newton, Kiley S. Graim, Colleen Mathis, Donghui Cheng, Joshua M. Stuart, Owen N. Witte · 2015 · Proceedings of the National Academy of Sciences
65. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
    Jordi Remón, Émilie Le Rhun, Benjamin Besse · 2016 · Cancer Treatment Reviews
66. Precision Oncology: The Road Ahead
    Daniela Senft, Mark D.M. Leiserson, Eytan Ruppin, Ze’ev A. Ronai · 2017 · Trends in Molecular Medicine
67. AXL kinase as a novel target for cancer therapy
    Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balázs Halmos · 2014 · Oncotarget
68. Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
    Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian Ada Zhan, Maysun Hasan, Shweta S. Chavan, Fanli Meng, Fathema Uddin, Parvathy Manoj, Mark T.A. Donoghue, Helen H. Won et al. · 2021 · Cancer Discovery
69. ALK-positive lung cancer: a moving target
    Jaime Laurel Schneider, Jessica J. Lin, Alice Tsang Shaw · 2023 · Nature Cancer
70. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
    Cabanos, Heidie Frisco, Hata, Aaron N. · 2021 · Cancers
71. N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
    Adeline Berger, Nicholas J. Brady, Rohan Bareja, Brian Robinson, Vincenza Conteduca, Michael A. Augello, Loredana Puca, Adnan Ahmed, Étienne Dardenne, Xiaodong Lü et al. · 2019 · Journal of Clinical Investigation
72. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Andrew J. Piper‐Vallillo, Lecia Van Dam Sequist, Zofia Piotrowska · 2020 · Journal of Clinical Oncology
73. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
    CHRISTOS CHOUAID, Cécile Dujon, Pascal Dô, I. Monnet, Anne Madroszyk, H. Le Caer, J.B. Auliac, Henri Berard, P. A. Thomas, H. Léna et al. · 2014 · Lung Cancer
74. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
    Pierre‐Emmanuel Colombo, Michel Fabbro, Charles G. Theillet, Frédéric Bibeau, Philippe Rouanet, Isabelle Laure Ray-Coquard · 2013 · Critical Reviews in Oncology/Hematology
75. Lung Cancer in the Era of Precision Medicine
    Katerina A. Politi, Roy S. Herbst · 2015 · Clinical Cancer Research
76. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
    Azhar Ali, Elena Levantini, Jun Ting Teo, Julian Goggi, John G. Clohessy, Chan Wu, Leilei Chen, Henry He Yang, Indira Krishnan, Olivier N. Kocher et al. · 2018 · EMBO Molecular Medicine
77. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance
    Roberta Minari, Paola Bordi, Marcello Tiseo · 2016 · Translational Lung Cancer Research
78. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
    Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, T. Koga, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Kenji Tomizawa, Toshiki Takemoto et al. · 2019 · Journal of Thoracic Oncology
79. Molecular events in neuroendocrine prostate cancer development
    Yong Wang, Yu Wang, Xinpei Ci, Stephen Y. C. Choi, Francesco Crea, Dong Lin, Yuzhuo Z. Wang · 2021 · Nature Reviews Urology
80. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
    Cortot, Alexis B., Repellin, Claire E., Shimamura, Takeshi, Capelletti, Marzia, Zejnullahu, Kreshnik, Ercan, Dalia, Christensen, James G., Wong, Kwok-Kin, Gray, Nathanael S., Jänne, Pasi A. · 2013 · Cancer Research
81. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
    Erik S. Knudsen, Steven C. Pruitt, Pamela A. Hershberger, Agnieszka Katarzyna Witkiewicz, David W. Goodrich · 2019 · Trends in cancer
82. Novel therapeutic targets on the horizon for lung cancer
    Wan-Ling Tan, Amit Jain, Angela Maria Takano, Evan William Newell, Narayanan Gopalakrishna Iyer, Wan‐Teck Lim, Eng-Huat Tan, Weiwei Zhai, Axel M. Hillmer, Wai Leong Tam et al. · 2016 · The Lancet Oncology
83. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
    Amit J. Sabnis, Trever Grant Bivona · 2019 · Trends in Molecular Medicine
84. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
    Seo‐Young Park, M.-H. Lee, Minjung Seong, S.T. Kim, Jin Hyoung Kang, Byoung Chul Cho, K.H. Lee, E.K. Cho, Jong‐Mu Sun, S.-H. Lee et al. · 2020 · Annals of Oncology
85. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
    Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
86. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
    Paul A. Bunn, John Dorrance Minna, Alexander Augustyn, Adi F. Gazdar, Youcef Ouadah, Mark A. Krasnow, Anton J. M. Berns, Elisabeth M. Brambilla, Natasha Rekhtman, Pierre P. Massion et al. · 2016 · Journal of Thoracic Oncology
87. NOTCH , ASCL1 , p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas
    Lydia Meder, Katharina König, Luka Ozretić, Anne Maria Schultheis, Frank Ueckeroth, Carsten Patrick Ade, Kerstin Albus, Diana Boehm, Ursula Rommerscheidt‐Fuss, Alexandra Florin et al. · 2015 · International Journal of Cancer
88. Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
    Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura et al. · 2017 · Cancer Research
89. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
    Nitin Roper, Anna‐Leigh Brown, Jun Stephen Wei, Svetlana Pack, Christopher Julius Trindade, Chul Kim, Olivia Restifo, Shaojian Gao, Sivasish Sindiri, Farid Rashidi Mehrabadi et al. · 2020 · Cell Reports Medicine
90. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
    Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Yoshikawa TACHIHARA, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma et al. · 2021 · JAMA Oncology
91. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    Ryan James Hartmaier, Aleksandra A. Markovets, Myung‐Ju Ahn, Lecia Van Dam Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena Alexandra Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee et al. · 2022 · Cancer Discovery
92. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations
    Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko, Imai, Yukihiro, Monden, Kazuya et al. · 2013 · Cancer
93. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities
    Michele De Palma, Douglas Hanahan · 2012 · Molecular Oncology
94. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
    Zachary Alan Yochum, Jessica Cades, Hailun Wang, Suman Chatterjee, Brian Wesley Simons, James P. O’Brien, Susheel K. Khetarpal, Ghali Lemtiri-Chlieh, Kayla V. Myers, Eric H.‐B. Huang et al. · 2018 · Oncogene
95. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations
    Riyaz N.H. Shah, Jason Francis Lester · 2019 · Clinical Lung Cancer
96. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
    Nilsson, Monique B., Sun, Huiying, Robichaux, Jacqulyne, Pfeifer, Matthias, McDermott, Ultan, Travers, Jon, Diao, Lixia, Xi, Yuanxin, Tong, Pan, Shen, Li et al. · 2020 · Science Translational Medicine
97. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer
    Vignot, Stéphane, Frampton, Garrett M., Soria, Jean-Charles, Yelensky, Roman, Commo, Frédéric, Brambilla, Christian, Palmer, Gary, Moro-Sibilot, Denis, Ross, Jeffrey S., Cronin, Maureen T. et al. · 2013 · Journal of Clinical Oncology
98. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance
    Meng‐Shih Weng, Jer‐Hwa Chang, Wen-Yueh Hung, Yi‐Chieh Yang, Ming‐Hsien Chien · 2018 · Journal of Experimental & Clinical Cancer Research
99. From human genome to cancer genome: The first decade
    David A. Wheeler, Linghua Wang · 2013 · Genome Research
100. Management of brain metastases according to molecular subtypes
     Riccardo Soffietti, Manmeet Singh Ahluwalia, NU Lin, Roberta Rudà · 2020 · Nature Reviews Neurology